FIRALIS GROUP

FIRALIS Group

- Firalis' projects target qualification of biomarkers for various clinical applications. As the initiator of SAFE-T consortium, Firalis validates and develops biomarker panels, following strictly EMA and FDA directions. Firalis has a comprehensive range of know-how for biomarker discovery up to clinical qualification, develops and commercializes biomarker tests, RUO and IVD tools for cardiovascular diseases

- Amoneta Diagnostics seeks, develops, and qualifies innovative biomarkers for the development of diagnostics in the field of neurological diseases.
The purpose of Amoneta Diagnostics is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice. Amoneta's know-how is based on the detection of blood biomarkers.

- Firalis constantly extends the range of its biomarker projects and product pipelines, while developing and commercializing first-in-market IVD tools.

- Amoneta provides advanced precision medicine tools aiding specialists to make personalized medical decisions, drive progress in disease characterization, and identify potential therapeutic targets.

We strive to improve patient care and disease diagnostic and advance precision medicine for better health for everyone.